Bone Marrow-Derived Stem Cell Transfer in Acute Myocardial Infarctions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00264316|
Recruitment Status : Completed
First Posted : December 12, 2005
Last Update Posted : January 17, 2013
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction||Procedure: bone marrow-derived stem cell transfer||Phase 2|
Despite early coronary reperfusion, salvage of ischemic myocardium is incomplete and loss of viable myocardium initiates a process of adverse left ventricular (LV) remodeling1, compromising clinical outcome.
Experimental data have suggested that autologous bone marrow-derived or circulating progenitor cells may be beneficial for LV function recovery, but underlying mechanisms are unclear and prominent cardiomyocyte transdifferentiation has only been reported under selected experimental conditions. Early non-randomized clinical investigations indicate feasibility, safety and enhanced functional recovery after autologous human bone marrow-derived stem cell (BMSC) infusion into the infarct-related artery. More recently, a randomized open study demonstrated improvement of LV systolic function but not of LV remodeling following BMSC transfer.
In the absence of trials, in which the control group reproduces the exact conditions of the cell transfer group, including bone marrow aspiration and a placebo intracoronary injection, the true benefit of cell transfer cannot be fully appreciated.
We, therefore, designed a randomized, double-blind, and placebo-controlled exploratory study to investigate the effect of autologous BMSC transfer on LV functional and structural recovery after myocardial infarction. In view of the exploratory nature of the study and to detect potential mechanisms for the biological effect, we also assessed myocardial perfusion and oxidative metabolism using serial 1-[11C]acetate positron emission tomography (PET).
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||68 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Double-blind, Randomised, Controlled Study of Autologous Bone Marrow-Derived Stem Cell Transfer In Patients With ST-Segment Elevation Myocardial Infarction.|
|Study Start Date :||May 2003|
|Study Completion Date :||December 2005|
- increase in global LV ejection fraction fraction; evaluation by magnetic resonance (MRI) after 4 months
- change in infarct size and regional LV function; evaluation by magnetic resonance (MRI) after 4 months
- change in myocardial perfusion and oxidative metabolism; investigated using serial 1-[11C]acetate positron emission tomography after 4 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00264316
|Department of Cardiology, University Hospital Gasthuisberg|
|Leuven, Belgium, 3000|
|Principal Investigator:||Stefan Janssens, MD, PhD||Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium|
|Study Director:||Frans Van de Werf, MD, PhD||Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium|